To hear about similar clinical trials, please enter your email below

Trial Title: Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC

NCT ID: NCT05484908

Condition: Immune-Mediated Hepatitis
Liver Failure
Hepatocellular Carcinoma

Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular
Liver Failure
Hepatic Insufficiency

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Other
Intervention name: DPMAS+LPE
Description: Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times in two weeks. The volume of plasma adsorption in DPMAS is 5000~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
Arm group label: DPMAS+LPE group

Intervention type: Other
Intervention name: PE
Description: Patients will receive treatment of plasma exchange (PE) for three times in two weeks. The volume of fresh frozen plasma used in PE is 2000 millilitre.
Arm group label: PE group

Intervention type: Other
Intervention name: Comprehensive internal medical treatment
Description: Patients will receive comprehensive internal medical treatment.
Arm group label: DPMAS+LPE group
Arm group label: PE group

Summary: This study aims to investigate the efficacy and safety of artificial liver support system treatment for immune checkpoint inhibitors related liver failure in patients with hepatocellular carcinoma.

Detailed description: Immune checkpoint inhibitors (ICIs) are commonly used for advanced stage of hepatocellular carcinoma (HCC) in recent years. The incident rate of Grade 4 immune checkpoint inhibitors-induced immune mediated hepatitis reaches 14.5%. Since these patients usually develop into liver failure, it is urgent to find out a more suitable therapy. Artificial liver support system (ALSS) treatment has been proved to effectively control both immune mediated hepatitis and liver failure, it may be a new therapy for immune checkpoint inhibitors-induced liver failure (ICIs-LF) in patients with HCC. Therefore, this study aims to investigate the efficacy and safety of ALSS treatment, including the classic mode of plasma exchange (PE) and new combination mode of double plasma molecular adsorption system (DPMAS) with sequential low-dose plasma exchange (LPE), for ICIs-LF in patients with HCC. Sixty patients with HCC and ICIs-LF will be enrolled in this study. The participants are randomly divided into trial group (DPMAS+LPE, and comprehensive internal medical treatment) and control group (PE and comprehensive internal medical treatment). Symptoms, signs, laboratory tests results, adverse events, mortality rates are recorded from treatment baseline to 12 weeks.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Age from 18 to 65 years old; 2. Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA > 0.5 year); 3. Clinical diagnosis of hepatocellular carcinoma and receive immune checkpoint inhibitors treatment. The last treatment of immune checkpoint inhibitors is less than three months from inclusion; 4. The level of hepatitis b virus DNA < 2000 IU/mL; 5. Serum aspartate aminotransferase/alanine aminotransferase > 20 times upper limit of normal;serum total bilirubin>10 times upper limit of normal; 6. Prothrombin time international ratio > 1.5; 7. Platelets > 50*10 E9/L; 8. Without intrahepatic bile duct dilation due to tumor progression. Exclusion Criteria: 1. Other active liver diseases; 2. Other malignancy; 3. Pregnancy or lactation; 4. Human immunodeficiency virus infection or congenital immune deficiency diseases; 5. Severe diabetes, autoimmune diseases; unstable infarction due to cardio-cerebrovascular events; other important organ dysfunctions or transplantation; 6. Active bleeding, disseminated intravascular coagulation, thrombosis, or thrombotic disease; 7. Patients received artificial liver support system treatment in one week before inclusion; 8. Patients can not follow-up; 9. Investigator considering inappropriate

Gender: All

Minimum age: 18 Years

Maximum age: 65 Years

Healthy volunteers: No

Locations:

Facility:
Name: Third Affiliated Hospital of Sun Yat-sen University

Address:
City: Guangzhou
Zip: 510630
Country: China

Status: Recruiting

Contact:
Last name: Wenxiong Xu, Doctor

Phone: +8613760783281
Email: xuwenx@mail.sysu.edu.cn

Start date: August 12, 2022

Completion date: August 31, 2024

Lead sponsor:
Agency: Third Affiliated Hospital, Sun Yat-Sen University
Agency class: Other

Source: Third Affiliated Hospital, Sun Yat-Sen University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05484908

Login to your account

Did you forget your password?